EGFR and non-small cell lung carcinoma: A single-arm phase II trial is ongoing to evaluate the efficacy of furmonertinib, a third-generation EGFR-TKI, combined with radiotherapy for EGFR-mutated NSCLC patients with Oligo-PD (NCT04970693).